parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.06 from other evidence	0.00
cell type Human Protein Atlas	group enriched, including oligodendrocytes; strongest in lymphatic endothelial cells	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 88	0.91
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 4509

receipt 4517: GJC2 in dopamine neurons, braak

power: full sample -0.11 (p 0.652, n 18), 95% CI -0.55 to +0.37. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.08 (p 0.748, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.13 (p 0.621, n 18). could be the mix.
skeptic: leave-one-out range -0.29 to +0.00, sign flips 1; without severely affected donors -0.11 (p 0.652, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GJC2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 4516: GJC2 in oligodendrocytes, braak

power: full sample -0.50 (p 0.036, n 18), 95% CI -0.78 to -0.04. the interval excludes zero: something may be there, smaller than a half can see.
confounder: adjusted for sex: -0.52 (p 0.027, n 18). holds up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.53 (p 0.024, n 18). not the mix.
skeptic: leave-one-out range -0.73 to -0.46, sign flips 0; without severely affected donors -0.50 (p 0.036, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GJC2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts